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Abstract 
Objective:To describe the clinical characteristics, treatment approaches, clinical outcomes and co-
morbidities of youth with type 2 diabetes (T2D) enrolled in the Pediatric Diabetes Consortium (PDC) 
T2D Registry. 
Methods:PDC enrolled 598 youth <21 years of age with T2Dfrom February 2012 -July 2015 at8centers. 
Data were collected from medical records and interviews with participants and/or parents and included 
HbA1c, diabetes treatments,prevalence of diabetescomorbidities(hypertension (HTN), dyslipidemia 
(DL), microalbuminuria(MA), and nonalcoholic fatty liver disease (NAFLD)). 
Results: 
Insulin use was observed in 45% ofthose with T2Dduration <1 year,44% for 1-<2 years, 55% for2-3 
years and60%for e4 years. Median HbA1c was 6.7% (50 mmol/mol),8.5% (69 mmol/mol), 9.6% (81 
mmol/mol), and 9.7% (82 mmol/mol) inthose with disease duration <1 year, 1-<2 years, 2-3 years and 
e4 years, respectively.Only 33% and 11% of those with HTNandDLrespectively, were being treated.  
MA and NAFLDwere observed in 5-6% of the participants. Prevalence of HTN was associated with 
higher BMI (p<0.001), DL with higher HbA1c (p<0.001), and MA with longer diabetes duration 
(p=0.001). 
Conclusions: 
 
Frequency of insulin therapy in youth with T2D was associated with increased disease duration and 
those with longer duration rarely achieve target HbA1c level. This highlights the aggressive course of 
T2D in youth and adolescents.  Additionally, co-morbidities are not being adequately treated. Follow up 
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datafrom the PDC will provide additional important information about the naturalhistory of T2D and 
patterns of gaps in treatment. 
 
Introduction 
Type 2 diabetes (T2D) is an increasingly serious health problem in children and adolescents in 
the United States, with complications that extend beyond the difficulty in achieving optimal glycemic 
control (1-8). It has emerged as an increasingly serious health problemwith complications thatextend 
beyond the difficulty in achieving optimal glycemic control(1-8).The young age of patients and the 
prevalence of co-morbidities, such as hypertension (HTN) and dyslipidemia (DL), contribute to the early 
development of retinopathy, nephropathy and increase the risk for future cardiovascular disease (CVD), 
the major cause of death in adults with T2D(2; 6-8).These co-morbidities occur earlierand progress 
rapidly in children and adolescents(6-8) even in those withgood metabolic control (2; 6-8). 
The Pediatric Diabetes Consortium (PDC) T2D Registry was established in 2012 to improve the 
care of children with T2D through sharing of best practices, collecting outcome data with a common 
database and collectively advocating for improvements in pediatric diabetes care focused on evidence. 
In this paper, the clinical characteristics, treatment approaches, clinical outcomes and co-morbidities of 
thefirst 598 youth with T2D enrolled in the Registry are described.   
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Methods 
The PDC enrolled 598 patients with T2D between February 2012 and July 2015.  The protocol 
was approved by the Institutional Review Boards (IRB) at each of the 8 participating centers at 
following locations: Houston, TX; Los Angeles, CA; Stanford, CA; Denver, CO; Gainesville, FL; New 
Haven, CT; Ann Arbor, MI; Philadephia, PA.  Informed consent was obtained from participantse18 
years of age and from parents of participants<18 years of age. Assent was obtained from participants per 
local IRB regulations at each center.Participantshad to be <21 years of age and diagnosed with using the 
criteria of the American Diabetes Association to be eligible for enrollment in the study.  
Diagnostic criteria for diabetes included a glycated hemoglobin (HbA1c) e6.5% (e48 
mmol/mol), random glucose >200 mg/dL (11.1 mmol/L), 2 hour post challenge glucose e200 mg/dL 
(11.1 mmol/L) or a fasting glucose e126mg/dL (7.0 mmol/L).Diagnostic criteria for T2D, once diabetes 
was diagnosed, included negative diabetes associated autoantibodies. If diabetes autoantibodies were not 
available at diagnosis, an elevated C-peptide (above the normal fasting level for the laboratory) and/or 
absence of insulin requirement at 6 months post-diagnosis were used to determine T2D. For enrollment, 
participants also had to have a weight percentile of e  85% for age and sex either at the time of diagnosis 
or prior to the weight loss associated with unrecognized diabetes. 
Data Collection 
Data were collected from medical records and from interviews with the participantsand/or 
parents.  Participant age, diagnosis information (presentation and diagnostic criteria, DKA status with 
associated lab results including HbA1c and physical examination results), treatment following diagnosis 
including insulin use, DKA and severe hypoglycemia events since diagnosis, frequency of home blood 
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glucosemonitoring,laboratory results including HbA1c, kidney function, and lipid profilefrom the time 
of diagnosis were obtained.The most recent laboratoryresults, physical examination findings, other 
medical conditions and medicationsalso wererecorded. 
Body mass index (BMI) was computed from height and weight measured by the health care 
provider within ±28 days of enrollment. BMI percentile and standard deviation score adjusted for age 
and gender were calculated using the 2000 CDC population growth chart data(9).  Likewise, blood 
pressure (BP) percentilesadjusted for age, gender, and height were calculated from the CDC charts(10).  
HTNwas defined as a medical problemnoted in the medical record as not resolved, currently being 
treated for HTN at enrollment,or a systolic or diastolic BP measurement e95th percentile for those age 
<18 years and systolic BP e140 or diastolic BP e  90 for those age e18 years within ±28 days of 
enrollment.  DL was defined as any of the following as noted in the medical record:unresolved 
hypertriglyceridemia, elevatedlow-density lipoprotein (LDL) cholesterol, or decreased high-density 
lipoprotein (HDL) cholesterol (based on descriptions from medical records, cut-points not available); 
currently being treated with medication for dyslipidemia; or a non-HDL cholesterol e145 mg/dL within 
±28 days of enrollment (fasting status not available). Microalbuminuria (MA)and non-alcoholic fatty 
liver disease (NAFLD) were defined as the patienthavingeach respectively as an ongoing medical 
condition at the time of enrollment.  
Statistical Analysis 
Prevalence of DL was calculated among those participants who participated an ancillary study at 
enrollment where blood samples were taken for multiple lab tests (N=298) in order to reduce bias caused 
by large amount of missing data in laboratory results. Prevalence of the other three comorbidities was 
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calculated among all the T2D participants enrolled (N=598).Both univariableand multivariablelogistic 
regression models were used to determine the association betweeneachof the comorbidities specified 
above with age, diabetes duration, BMI and HbA1c as continuous variables. These factors were selected 
based on clinical factors that have been suggested as contributing to the development of HTN, DL and 
MA in diabetes, including the TODAY study in adolescents with type 2 diabetes(6). 
No formal adjustment was made for multiple comparisons; only p-values<0.01 were considered 
to be statistically significant.All reported p-values are two-sided. All analyses were conducted using 
SAS version 9.4 (SAS Institute, Cary, NC). 
Results 
As shown in Table 1, the 598 participants included in the analyses had a median (interquartile 
range) age of 16.0years (14.0-17.7 years) at enrollment. Median (interquartile range) diabetes duration 
was 2.0 (0.7-4.2) years at enrollment. The majority wasfemale (63%), Hispanic (55%) and had a family 
history of diabetes (92%). Only 31% had a parent with education beyondhigh school and 64% had 
Children’s Health Plan or other government health insurance. Eighty-five percent of the participants 
were obese (BMI >95th percentile for age and gender) and 41% had a BMI >99th percentile for age and 
gender. Eleven percent had at least one episode of diabetic ketoacidosis (DKA) since diagnosis. Only 
2% had a severe hypoglycemic (SH) event that resulted in loss of consciousness or seizure. 
At enrollment, 35% (N=208) of participants were being treated with metformin alone, 19% 
(N=111) with insulin alone, 31% (N=186) with both metformin and insulin, 13% (N=75) with lifestyle 
modification alone, and only 3% (N=18) were treated with other glucose-lowering medications 
with/without metformin or insulin. Overall, 51% of participants were using insulin at enrollment.The 
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overall median (interquartile range) HbA1c was 7.3% (56 mmol/mol) [interquartile range 6.0-9.4% (42-
79 mmol/mol)], 46% were <7% (53 mmol/mol) and 29% were e9% (75 mmol/mol).  As shown in 
Figure 1 and Table 2, HbA1c levels were lower in participants treated with lifestyle or metformin 
alone.For those treated with lifestyle modifications alone in the <1 year and 1-<2 year duration group, 
median HbA1c levels were in high prediabetic and diabetic range respectively. 
However, insulin use increased with increasing duration of T2D. Insulin use was observed in 
45% of those with disease duration < 1 year and 44% of those with diabetes duration 1-<2 years; this 
increased to 55% for2-3 years and60% for e4 years. HbA1c levels also increased from 6.7% (50 
mmol/mol) to 8.5% (69 mmol/mol), 9.6% (81 mmol/mol) and 9.7% (82 mmol/mol) among those 
usinginsulin with T2D duration <1 year, 1-<2 years, 2-3 years and e4 years respectively. 
At the time of enrollment, 31% had HTN,44% had DL, 6% had MA,and 5% hadNAFLD(Table 
3). However, only 33% of the participants who had HTN and 11% of those who had DL were being 
treatedwith medicationfor the respective condition at the time of enrollment. HTN was associated with 
higher BMI (p<0.001) while DL was associated with higher HbA1c (p<0.001), and MA with longer 
diabetes duration (p=0.001). The prevalence of DL also trended higher among those participants with 
older age (p=0.02). No associationswere detected withNAFLD.Results from multivariate regression 
models were similar. 
Discussion 
Enrollment data from the PDC T2D Registry provide a cross-sectional view of the current 
clinicalmanagement and outcomes of treatment of youth with T2D. Consistent with previous 
studies(11), this disease disproportionally affects girls from disadvantaged Black and Hispanic/Latino 
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families. While all participantswere requiredto have a BMI >85th percentile around the time of diagnosis 
to qualify for entry in the Registry, very few of the participants had lowered their BMI percentiles into 
the normal range at the time of enrollment.  
Treatment with insulinwas common in the early phase of the disease(<1 year), which was likely 
being employed to rapidly reverse gluco-toxicity around the time of diagnosis. This interpretation is 
consistent with the relatively low mean A1c levels in these subjects and with the results of the run-in 
phase of the TODAY study, where the majority of adolescents during the first 1-2 years could be 
weaned off insulin treatment without adversely affecting metabolic control(12). However, most of  our 
subjects with longer disease duration who were treated with insulin either alone or in combination with 
metformin had mean A1c levels that were > 9.0%; values that were much higher than the target A1c 
levels of <7.5% currently recommended by the American Diabetes Association and the International 
Society for Pediatric and Adolescent Diabetes (13). This observation may be reflective of a decline of ² -
cell function previously reported  in youth with T2D, which appears to be much more rapid than in 
adults with T2D(4; 14; 15). 
A majority of the participants treated with lifestyle modifications alone had A1c e6% and those 
with A1c in the diabetic range, who could have clearly benefitted from pharmacological intervention, 
were not prescribed metformin. The reason behind the undertreatment is not clear but could be 
multifactorial including poor follow up. It should also be noted that many of our subjects were enrolled  
in the registry prior to publication of the ISPAD clinical practice guidlelines (2014) for treatment of 
youth with type 2 diabetes, which recommended early treatment with metformin along with lifestyle 
modifications  for all youth with T2D(16). Physical activity remains imperative in management of T2D 
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in adolescents(17) and barriers to better compliance with lifestyle modifications must be recognized and  
addressed. 
As seen in other pediatric T2D populations(6-8; 18-20), co-morbidities and other risk factors for 
microvascular and macrovascular disease were prevalent in a large proportion of participantsin the PDC 
T2DRegistry. Another theme that emerges from these data is that many of the participants with elevated 
blood pressure and abnormal lipid levels at the time of enrollment in the Registry were not being treated 
for hypertension or dyslipidemia. The same trend of low treatment rates of hypertension in children with 
T2D has also been reported in other studies(15; 20). In the SEARCH study, 9% of T2D patients were 
diagnosed with dyslipidemia but only 5 % of the cohort was on lipid lowering medications(19). It is of 
concern that in the TODAY study, deterioration of both the atherogenic lipid profile and inflammatory 
markers occurred rapidly over the course of 3 years despite treatment with statins and intensive 
intervention by study personnel to attempt to achieve adherence to taking their lipid-lowering 
medication(8). It is anticipated that adherence to prescribed medications, will be even lower in a non-
study setting.  
The prevalence of microalbuminuria in the PDC T2D Registry is similar to that seen at study 
onset in the TODAY Study (6.4 versus 6.3%, respectively) but lower than the 16.6% prevalence of 
microalbuminuria at the end of the TODAY study three years later(6).  However, similar to the TODAY 
participants, the prevalence of microalbuminuria in our cohort increased with increasing duration of the 
disease. 
The strengths of the PDC T2D Registryinclude the size of the cohortas well as the inclusion of a 
cohortthat provides a snap shot of real life practices.The data were obtained from 8 academic pediatric 
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diabetes treatment centers in the US and thus reflect the current outpatient management of pediatric 
T2D. This contrasts with many clinical trials in pediatric T2D, in which clinical outcomes in highly 
selected cohorts of patients managed with structured treatment protocols are described.  
However, certain limitations of this study should also be noted. As the cohort was enrolled only 
from large pediatric centers, the results of the analyses may not be wholly representative of the entire US 
pediatric T2D population. Additionally, as diagnosis of T2D of the participants was obtained from 
medical records, there is a small possibility of missing undiagnosed T2D adolescents. The presence of 
co-morbidities was determined from the medical record ‘problem list’ which is dependent on the 
medical provider recording this. Therefore we may be underestimating the frequency of co-morbidities 
in this population. Also, fasting status and medication report were not available for all participants and 
may have affected the data interpretation at enrollment. Finally, this is a cross-sectional analysis,andone 
cannot infer longitudinal trends from the data even though duration of diabetes varies among the 
participants. Nonetheless, the findings of these initial analyses serve to underscore many of the special 
challenges that clinicians face in treating children and adolescents with T2D. Many patients are from 
disadvantaged, minority families, where socio-economic factors make compliance with treatment 
regimens more difficult. Moreover, metformin and insulin remain the only pharmacological treatment 
options approved for treatment of youth with T2D and, due to the difficulties in performing 
pharmaceutical trials in this population, it is unlikely that new drugs will be approved for treatment of 
pediatric T2D in the near future(21).  Hopefully, the collaborative efforts of the PDC will facilitate well-
controlled studies to evaluate novel therapies and strategies for T2D and associated comorbidities in this 
population. 
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Lastly, the observation of low rates of treatment of hypertension and dyslipidemia in the PDC 
T2D Registry is of concern.Despite clear guidelines from the ADA with respect to identification and 
treatment of co-morbidities in children with T2D, it does not appear that these co-morbidities are being 
adequately treated even in academic pediatric diabetes centers.  The reason for the low treatment rates 
needs further study. As atherosclerosis begins in childhood(22; 23), increased screening and an 
aggressive approach to glycemic control and treating co-morbidities should be encouraged in order to 
delay or prevent cardiovascular disease during the lifetime of our patients. 
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Table 1: Participant Characteristics at Enrollment (N=598a) 
 # % 
Age (years)   
 <13 95 16% 
 13−<15 129 22% 
 15−<18 251 42% 
 18−<21 123 21% 
median (25th,75th percentiles) 16.0 (14.0-17.7) 
Gender   
Male 222 37% 
Female 376 63% 
Race/Ethnicity   
White 50 8% 
Hispanic or Latino 328 55% 
Black/African American 175 30% 
Other/Multiple Race 39 7% 
Parent Education   
High School or Less 382 69% 
Associate 76 14% 
Bachelor 64 12% 
Master/Professional Degree 30 5% 
Health Insurance   
Private 166 28% 
Children’s Health Planor Other Government 382 64% 
Military 4 <1% 
None 46 8% 
Family History of Diabetes 538 92% 
Diabetes Duration (years)   
<1 185 31% 
1-<2 118 20% 
2-<4 134 22% 
e4 161 27% 
median (25th, 75th percentiles) 2.0 (0.7-4.2) 
BMI Percentileb(%)   
 <85 18 3% 
 85−<95 66 12% 
 95−<99 242 44% 
 e99 229 41% 
 median (25th, 75th percentiles) 99 (97-99) 
HbA1c % (mmol/mol)   
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 <6.0 (<42) 133 25% 
 6.0−<7.0 (42−<53) 117 22% 
 7.0−<8.0 (53−<64) 77 14% 
 8.0−<9.0 (64−<75) 57 11% 
 e9.0 (e75) 158 29% 
median (25th, 75th percentiles) 
7.3 (6.0-9.4) 
[56 (42-79)] 
   
Participants with any DKA Event since Diagnosis 66 11% 
DKA Events Rate (# events/100 person-year) 19.8 
  
Participants with any Severe Hypoglycemia (SH) 
Events since Diagnosis 11 2% 
SH Events Rate (# events/100 person-year) 1.3 
   
Insulin Use 306 51% 
Insulin Delivery Modality   
Pump 1 <1% 
1 daily injection 72 24% 
2-3 daily injections 147 49% 
e4 daily injections 82 27% 
Insulin Dose (units/Kg/day)   
<0.3 81 27% 
0.3-<0.5 65 22% 
0.5-<0.8 80 27% 
e0.8 71 24% 
 median (25th, 75th percentiles) 0.5 (0.3-0.8) 
Self-Monitoring Blood Glucose (# tests/day)c   
0 83 14% 
1 119 20% 
2-3 276 46% 
e4 120 20% 
 median (25th, 75th percentiles) 2 (1-3) 
a. Number of participants with missing or “Unknown” data: race/ethnicity (6), parent education (46), family history 
(12), BMI (43), HbA1c (56), insulin delivery modality (4) and insulin dose (9). 
b. BMI percentiles adjusted for age and gender based on 2000 CDC growth charts and excluded those > 20 years of 
age. 
c. Self-reported values. 
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Table 2: HbA1c Levels at Enrollment by Diabetes Duration and Treatment (N=542) 
Diabetes  
Duration 
Diabetes 
Treatment 
HbA1c % [mmol/mol] 
Na Median (25th, 75th percentiles) 
0-<1 years 
Overall 167 6.5 (5.7-7.9) [48 (39-63)] 
Life-style alone−no meds  27 6.4 (5.7-7.9) [46 (39-63)] 
metformin alone  62 6.5 (5.7-7.1) [47 (39-54)] 
insulin alone  26 6.9 (6.0-9.1) [52 (42-76)] 
metformin + insulin  52 6.6 (5.7-8.5) [49 (39-69)] 
other med ± insulin / metformin  0 NA 
1-<2 years 
Overall 110 7.3 (6.1-8.9) [56 (43-74)] 
Life-style alone−no meds  14 7.0 (6.1-7.8) [53 (43-62)] 
metformin alone  44 6.2 (5.6-7.0) [44 (38-53)] 
insulin alone  17 7.6 (6.5-10.1) [60 (48-87)] 
metformin + insulin  32 8.9 (7.5-10.3) [74 (58-89)] 
other medb± insulin / metformin  3 7.9 (7.7-7.9) [63 (61-63)] 
2-<4 years 
Overall 125 7.8 (5.8-10.2) [62 (40-88)] 
Life-style alone−no meds  15 5.8 (5.5-8.2) [40 (37-66)] 
metformin alone  41 5.8 (5.4-6.3) [40 (36-45)] 
insulin alone  28 9.6 (8.3-12.6) [81 (68-114)] 
metformin + insulin  38 9.5 (7.8-10.7) [80 (62-93)] 
other medc± insulin / metformin  3 8.8 (7.3-8.9) [73 (56-74)] 
e4 years 
Overall 140 8.4 (6.3-10.6) [68 (45-90)] 
Life-style alone−no meds  7 6.0 (5.9-6.2) [42 (41-44)] 
metformin alone  36 6.2 (5.6-7.3) [44 (38-57)] 
insulin alone  28 9.3 (8.2-11.3) [78 (66-100)] 
metformin + insulin  58 9.7 (7.7-11.9) [82 (61-107)] 
other medd± insulin / metformin  11 8.2 (7.1-10.2) [66 (54-88)] 
a. Number with HbA1c data available. 
b. Other diabetes medications including liraglutideand exenatide. 
c. Other diabetes medications including glipizide, glyburide, and pioglitazone. 
d. Other diabetes medications includingexenatide, glipizide, glyburide plus metformin,liraglutide, pioglitazone and 
repaglinide. 
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Table 3:Factors Associated with Comorbidities at Enrollment 
 N HTa DLa MAa NAFLDa 
Overall 598 31% 44% 6% 5% 
Age      
 <13 years 95 26% 28% 2% 5% 
 13−<15 years 129 30% 39% 9% 2% 
 15−<18 years 251 33% 49% 5% 6% 
 18−<21 years 123 31% 48% 10% 7% 
 p-valueb  0.41 0.02 0.12 0.33 
T2D Duration      
 <1 year 185 23% 40% 3% 4% 
 1-<2 years 118 38% 31% 8% 5% 
2-<4 years 134 39% 58% 6% 4% 
 e4 years 161 29% 46% 10% 7% 
 p-valueb  0.43 0.47 0.001 0.46 
BMIc,d      
<85% 18 17% 36% 22% 6% 
85%-<95% 66 20% 48% 3% 3% 
95%-<99% 242 30% 46% 6% 4% 
e99% 229 39% 43% 7% 7% 
 p-valueb  <0.001 0.76 0.06 0.28 
HbA1cd,e% (mmol/mol)      
 <6.0 (<42) 133 31% 28% 5% 6% 
 6.0−<7.0 (42−<53) 117 25% 37% 3%  5% 
 7.0−<8.0 (53−<64) 77 34% 52% 10% 8% 
 8.0−<9.0 (64−<75) 57 39% 65% 9% 5% 
 e9.0 (e75) 158 35% 58% 9% 3% 
 p-valueb  0.51 <0.001 0.08 0.24 
a. Abbreviations: HT – hypertension; DL – dyslipidemia; MA – microalbuminuria; NAFLD – non-alcoholic fatty liver 
disease. 
b. Not adjusted for multiple comparisons.  P-value from logistic regression model using continuous variable as 
predictor. 
c. BMI percentiles adjusted for age and gender based on 2000 CDC growth charts and excluded those < 2 and > 20 
years of age.  Missing for N=42 cases. 
d. Within ±28 days from enrollment. 
e. HbA1c missing forN=56 cases. 
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Figure 1: HbA1c Levels by Diabetes Treatment at Enrollment. The bottom and top of each box 
denote the 25th and 75th percentiles, the line inside the box denotes the median and the dot is the mean. 
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